X

Download About Juvenile Rheumatoid Arthritis PowerPoint Presentation

SlidesFinder-Advertising-Design.jpg

Login   OR  Register
X


Iframe embed code :



Presentation url :

Home / Health & Wellness / Health & Wellness Presentations / About Juvenile Rheumatoid Arthritis PowerPoint Presentation

About Juvenile Rheumatoid Arthritis PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

PowerPoint is the world's most popular presentation software which can let you create professional About Juvenile Rheumatoid Arthritis powerpoint presentation easily and in no time. This helps you give your presentation on About Juvenile Rheumatoid Arthritis in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this About Juvenile Rheumatoid Arthritis powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by slidesfinder in Health & Wellness ppt presentation category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

About This Presentation

About Juvenile Rheumatoid Arthritis Presentation Transcript

Slide 1 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP
Slide 2 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium
Slide 3 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age.
Slide 4 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis.
Slide 5 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic
Slide 6 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks
Slide 7 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process.
Slide 8 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2.
Slide 9 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977.
Slide 10 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005
Slide 11 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA
Slide 12 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005
Slide 13 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001
Slide 14 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years.
Slide 15 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA).
Slide 16 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach
Slide 17 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s…
Slide 18 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times.
Slide 19 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older.
Slide 20 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection.
Slide 21 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection. 21 Treatment of JRA DMARDs and Biologic DMARDs Methotrexate (MTX): used when NSAIDs fail to bring relief. Indicated for polyarticular JRA. MTX is the most widely used DMARD for JRA treatment. Starting dose 7.5 mg/m2 per week; maximum dose of 15 mg/m2 per week. Methotrexate compared to leflunomide (Lef): 240 JRA pts, 16-week DB + 6 mo Ext + optional 30 mo Ext in JRA; JRA Definition of Improvement > 30% (JRA DOI > 30): 89% MTX compared to 68% Lef. Adverse events: stomatitis, leukopenia, nausea/ abdominal pain, gastrointestinal bleeding, anorexia, malaise, fatigue, chills and fever, headache, alopecia, rash, decreased resistance to infection, elevated hepatic enzymes.
Slide 22 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection. 21 Treatment of JRA DMARDs and Biologic DMARDs Methotrexate (MTX): used when NSAIDs fail to bring relief. Indicated for polyarticular JRA. MTX is the most widely used DMARD for JRA treatment. Starting dose 7.5 mg/m2 per week; maximum dose of 15 mg/m2 per week. Methotrexate compared to leflunomide (Lef): 240 JRA pts, 16-week DB + 6 mo Ext + optional 30 mo Ext in JRA; JRA Definition of Improvement > 30% (JRA DOI > 30): 89% MTX compared to 68% Lef. Adverse events: stomatitis, leukopenia, nausea/ abdominal pain, gastrointestinal bleeding, anorexia, malaise, fatigue, chills and fever, headache, alopecia, rash, decreased resistance to infection, elevated hepatic enzymes. 22 Treatment of JRA DMARDs and Biologic DMARDs (Continued) Sulfasalazine Indicated for polyarticular JRA who have responded inadequately to salicylates or other non-steroidal anti-inflammatory drugs. Children 6 yrs and older: 40 - 60 mg/kg/day divided into 3 to 6 doses. Maintenance dose: 30 mg/kg/day divided into 4 doses. Adverse events: anorexia, headache, vomiting, gastric distress, rash, urticaria, hemolytic anemia.
Slide 23 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection. 21 Treatment of JRA DMARDs and Biologic DMARDs Methotrexate (MTX): used when NSAIDs fail to bring relief. Indicated for polyarticular JRA. MTX is the most widely used DMARD for JRA treatment. Starting dose 7.5 mg/m2 per week; maximum dose of 15 mg/m2 per week. Methotrexate compared to leflunomide (Lef): 240 JRA pts, 16-week DB + 6 mo Ext + optional 30 mo Ext in JRA; JRA Definition of Improvement > 30% (JRA DOI > 30): 89% MTX compared to 68% Lef. Adverse events: stomatitis, leukopenia, nausea/ abdominal pain, gastrointestinal bleeding, anorexia, malaise, fatigue, chills and fever, headache, alopecia, rash, decreased resistance to infection, elevated hepatic enzymes. 22 Treatment of JRA DMARDs and Biologic DMARDs (Continued) Sulfasalazine Indicated for polyarticular JRA who have responded inadequately to salicylates or other non-steroidal anti-inflammatory drugs. Children 6 yrs and older: 40 - 60 mg/kg/day divided into 3 to 6 doses. Maintenance dose: 30 mg/kg/day divided into 4 doses. Adverse events: anorexia, headache, vomiting, gastric distress, rash, urticaria, hemolytic anemia. 23 Treatment in JRA DMARDs and Biologic DMARDs (Continued) ENBREL (etanercept): a cytokine antagonist Indicated for moderate to severe polyarticular course JRA patients 4 to 17 years of age who had an inadequate response to one or more DMARDs. Dosage: 0.4 mg/kg/week (maximum 25 mg/ dose given twice weekly) as subcutaneous injection pre-filled syringe, 72-96 hrs. apart. Adverse events: headache, nausea, abdominal pain, and vomiting. Infection was reported in 43 of 69 (62%) of JRA patients during the 3-month (open-label phase). Serious AEs reported in the study: varicella, gastroenteritis, depression/ personality disorder, cutaneous ulcer, esophagitis/ gastritis, group A streptococcal septic shock, Type 1 diabetes, soft tissue and post-operative wound infection.
Slide 24 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection. 21 Treatment of JRA DMARDs and Biologic DMARDs Methotrexate (MTX): used when NSAIDs fail to bring relief. Indicated for polyarticular JRA. MTX is the most widely used DMARD for JRA treatment. Starting dose 7.5 mg/m2 per week; maximum dose of 15 mg/m2 per week. Methotrexate compared to leflunomide (Lef): 240 JRA pts, 16-week DB + 6 mo Ext + optional 30 mo Ext in JRA; JRA Definition of Improvement > 30% (JRA DOI > 30): 89% MTX compared to 68% Lef. Adverse events: stomatitis, leukopenia, nausea/ abdominal pain, gastrointestinal bleeding, anorexia, malaise, fatigue, chills and fever, headache, alopecia, rash, decreased resistance to infection, elevated hepatic enzymes. 22 Treatment of JRA DMARDs and Biologic DMARDs (Continued) Sulfasalazine Indicated for polyarticular JRA who have responded inadequately to salicylates or other non-steroidal anti-inflammatory drugs. Children 6 yrs and older: 40 - 60 mg/kg/day divided into 3 to 6 doses. Maintenance dose: 30 mg/kg/day divided into 4 doses. Adverse events: anorexia, headache, vomiting, gastric distress, rash, urticaria, hemolytic anemia. 23 Treatment in JRA DMARDs and Biologic DMARDs (Continued) ENBREL (etanercept): a cytokine antagonist Indicated for moderate to severe polyarticular course JRA patients 4 to 17 years of age who had an inadequate response to one or more DMARDs. Dosage: 0.4 mg/kg/week (maximum 25 mg/ dose given twice weekly) as subcutaneous injection pre-filled syringe, 72-96 hrs. apart. Adverse events: headache, nausea, abdominal pain, and vomiting. Infection was reported in 43 of 69 (62%) of JRA patients during the 3-month (open-label phase). Serious AEs reported in the study: varicella, gastroenteritis, depression/ personality disorder, cutaneous ulcer, esophagitis/ gastritis, group A streptococcal septic shock, Type 1 diabetes, soft tissue and post-operative wound infection. 24 Treatment in JRA DMARDs indicated for RA without an indication for JRA Hydroxychloroquine, injectable gold, leflunomide and d-penicillamine. Other Immunomodulatory or Cytotoxic Drugs Indicated in RA without a JRA indication: Azathioprine Cyclosporine A Without a RA or a JRA indication: Chlorambucil Thalidomide
Slide 25 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection. 21 Treatment of JRA DMARDs and Biologic DMARDs Methotrexate (MTX): used when NSAIDs fail to bring relief. Indicated for polyarticular JRA. MTX is the most widely used DMARD for JRA treatment. Starting dose 7.5 mg/m2 per week; maximum dose of 15 mg/m2 per week. Methotrexate compared to leflunomide (Lef): 240 JRA pts, 16-week DB + 6 mo Ext + optional 30 mo Ext in JRA; JRA Definition of Improvement > 30% (JRA DOI > 30): 89% MTX compared to 68% Lef. Adverse events: stomatitis, leukopenia, nausea/ abdominal pain, gastrointestinal bleeding, anorexia, malaise, fatigue, chills and fever, headache, alopecia, rash, decreased resistance to infection, elevated hepatic enzymes. 22 Treatment of JRA DMARDs and Biologic DMARDs (Continued) Sulfasalazine Indicated for polyarticular JRA who have responded inadequately to salicylates or other non-steroidal anti-inflammatory drugs. Children 6 yrs and older: 40 - 60 mg/kg/day divided into 3 to 6 doses. Maintenance dose: 30 mg/kg/day divided into 4 doses. Adverse events: anorexia, headache, vomiting, gastric distress, rash, urticaria, hemolytic anemia. 23 Treatment in JRA DMARDs and Biologic DMARDs (Continued) ENBREL (etanercept): a cytokine antagonist Indicated for moderate to severe polyarticular course JRA patients 4 to 17 years of age who had an inadequate response to one or more DMARDs. Dosage: 0.4 mg/kg/week (maximum 25 mg/ dose given twice weekly) as subcutaneous injection pre-filled syringe, 72-96 hrs. apart. Adverse events: headache, nausea, abdominal pain, and vomiting. Infection was reported in 43 of 69 (62%) of JRA patients during the 3-month (open-label phase). Serious AEs reported in the study: varicella, gastroenteritis, depression/ personality disorder, cutaneous ulcer, esophagitis/ gastritis, group A streptococcal septic shock, Type 1 diabetes, soft tissue and post-operative wound infection. 24 Treatment in JRA DMARDs indicated for RA without an indication for JRA Hydroxychloroquine, injectable gold, leflunomide and d-penicillamine. Other Immunomodulatory or Cytotoxic Drugs Indicated in RA without a JRA indication: Azathioprine Cyclosporine A Without a RA or a JRA indication: Chlorambucil Thalidomide 25 Treatment of JRA in 2006 Pauciarticular 25% to 33% will respond to NSAIDs; Patients not responsive to NSAIDS after 4 - 6 weeks with flexion contractures or leg length discrepancy  intra-articular corticosteroids. Patients with extended pauciarticular JRA or small joint involvement  treat as polyarticular JRA. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, pp 1671-1684.
Slide 26 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection. 21 Treatment of JRA DMARDs and Biologic DMARDs Methotrexate (MTX): used when NSAIDs fail to bring relief. Indicated for polyarticular JRA. MTX is the most widely used DMARD for JRA treatment. Starting dose 7.5 mg/m2 per week; maximum dose of 15 mg/m2 per week. Methotrexate compared to leflunomide (Lef): 240 JRA pts, 16-week DB + 6 mo Ext + optional 30 mo Ext in JRA; JRA Definition of Improvement > 30% (JRA DOI > 30): 89% MTX compared to 68% Lef. Adverse events: stomatitis, leukopenia, nausea/ abdominal pain, gastrointestinal bleeding, anorexia, malaise, fatigue, chills and fever, headache, alopecia, rash, decreased resistance to infection, elevated hepatic enzymes. 22 Treatment of JRA DMARDs and Biologic DMARDs (Continued) Sulfasalazine Indicated for polyarticular JRA who have responded inadequately to salicylates or other non-steroidal anti-inflammatory drugs. Children 6 yrs and older: 40 - 60 mg/kg/day divided into 3 to 6 doses. Maintenance dose: 30 mg/kg/day divided into 4 doses. Adverse events: anorexia, headache, vomiting, gastric distress, rash, urticaria, hemolytic anemia. 23 Treatment in JRA DMARDs and Biologic DMARDs (Continued) ENBREL (etanercept): a cytokine antagonist Indicated for moderate to severe polyarticular course JRA patients 4 to 17 years of age who had an inadequate response to one or more DMARDs. Dosage: 0.4 mg/kg/week (maximum 25 mg/ dose given twice weekly) as subcutaneous injection pre-filled syringe, 72-96 hrs. apart. Adverse events: headache, nausea, abdominal pain, and vomiting. Infection was reported in 43 of 69 (62%) of JRA patients during the 3-month (open-label phase). Serious AEs reported in the study: varicella, gastroenteritis, depression/ personality disorder, cutaneous ulcer, esophagitis/ gastritis, group A streptococcal septic shock, Type 1 diabetes, soft tissue and post-operative wound infection. 24 Treatment in JRA DMARDs indicated for RA without an indication for JRA Hydroxychloroquine, injectable gold, leflunomide and d-penicillamine. Other Immunomodulatory or Cytotoxic Drugs Indicated in RA without a JRA indication: Azathioprine Cyclosporine A Without a RA or a JRA indication: Chlorambucil Thalidomide 25 Treatment of JRA in 2006 Pauciarticular 25% to 33% will respond to NSAIDs; Patients not responsive to NSAIDS after 4 - 6 weeks with flexion contractures or leg length discrepancy  intra-articular corticosteroids. Patients with extended pauciarticular JRA or small joint involvement  treat as polyarticular JRA. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, pp 1671-1684. 26 Treatment of JRA in 2006 Polyarticular RF (-) or (+), NSAID (symptom control) alone is usually not as effective as a NSAID + DMARD. NSAID trial for several weeks  add oral MTX. If oral MTX is not effective  parenteral route MTX. If NSAID + MTX (oral or parenteral) is not effective  anti-TNF medication. No current evidence whether a combination of MTX + anti-TNF medication are more effective than only anti-TNF medication. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, pp 1671-1684.
Slide 27 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection. 21 Treatment of JRA DMARDs and Biologic DMARDs Methotrexate (MTX): used when NSAIDs fail to bring relief. Indicated for polyarticular JRA. MTX is the most widely used DMARD for JRA treatment. Starting dose 7.5 mg/m2 per week; maximum dose of 15 mg/m2 per week. Methotrexate compared to leflunomide (Lef): 240 JRA pts, 16-week DB + 6 mo Ext + optional 30 mo Ext in JRA; JRA Definition of Improvement > 30% (JRA DOI > 30): 89% MTX compared to 68% Lef. Adverse events: stomatitis, leukopenia, nausea/ abdominal pain, gastrointestinal bleeding, anorexia, malaise, fatigue, chills and fever, headache, alopecia, rash, decreased resistance to infection, elevated hepatic enzymes. 22 Treatment of JRA DMARDs and Biologic DMARDs (Continued) Sulfasalazine Indicated for polyarticular JRA who have responded inadequately to salicylates or other non-steroidal anti-inflammatory drugs. Children 6 yrs and older: 40 - 60 mg/kg/day divided into 3 to 6 doses. Maintenance dose: 30 mg/kg/day divided into 4 doses. Adverse events: anorexia, headache, vomiting, gastric distress, rash, urticaria, hemolytic anemia. 23 Treatment in JRA DMARDs and Biologic DMARDs (Continued) ENBREL (etanercept): a cytokine antagonist Indicated for moderate to severe polyarticular course JRA patients 4 to 17 years of age who had an inadequate response to one or more DMARDs. Dosage: 0.4 mg/kg/week (maximum 25 mg/ dose given twice weekly) as subcutaneous injection pre-filled syringe, 72-96 hrs. apart. Adverse events: headache, nausea, abdominal pain, and vomiting. Infection was reported in 43 of 69 (62%) of JRA patients during the 3-month (open-label phase). Serious AEs reported in the study: varicella, gastroenteritis, depression/ personality disorder, cutaneous ulcer, esophagitis/ gastritis, group A streptococcal septic shock, Type 1 diabetes, soft tissue and post-operative wound infection. 24 Treatment in JRA DMARDs indicated for RA without an indication for JRA Hydroxychloroquine, injectable gold, leflunomide and d-penicillamine. Other Immunomodulatory or Cytotoxic Drugs Indicated in RA without a JRA indication: Azathioprine Cyclosporine A Without a RA or a JRA indication: Chlorambucil Thalidomide 25 Treatment of JRA in 2006 Pauciarticular 25% to 33% will respond to NSAIDs; Patients not responsive to NSAIDS after 4 - 6 weeks with flexion contractures or leg length discrepancy  intra-articular corticosteroids. Patients with extended pauciarticular JRA or small joint involvement  treat as polyarticular JRA. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, pp 1671-1684. 26 Treatment of JRA in 2006 Polyarticular RF (-) or (+), NSAID (symptom control) alone is usually not as effective as a NSAID + DMARD. NSAID trial for several weeks  add oral MTX. If oral MTX is not effective  parenteral route MTX. If NSAID + MTX (oral or parenteral) is not effective  anti-TNF medication. No current evidence whether a combination of MTX + anti-TNF medication are more effective than only anti-TNF medication. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, pp 1671-1684. 27 Treatment of JRA in 2006 Systemic NSAIDs 2 to 3 weeks with caution  risk of Disseminated Intravascular Coagulation (DIC), (macrophage activation syndrome); Intravenous pulse methylprednisolone; Oral corticosteroids  Lowest effective dose; Steroid sparing  immunomodulatory approach is under evaluation for steroid sparing effects. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, p1671-1684.
Slide 28 - 1 Juvenile Rheumatoid Arthritis Arthritis Advisory Committee Meeting Division of Anesthesia, Analgesia and Rheumatology Products November 29, 2006 Carolyn L. Yancey, MD Medical Officer, DAARP 2 AGENDA Juvenile Rheumatoid Arthritis Epidemiology, Pathogenesis and Etiology Classification of Juvenile Rheumatoid Arthritis American College of Rheumatology (ACR) Criteria Clinical Manifestations Disease Course and Prognosis Treatment of JRA and the State-of-the-Art Treatment Armamentarium 3 BACKGROUND Chronic Arthritis in Childhood characterized as Juvenile Rheumatoid Arthritis JRA Age of onset < 16 years of age. 4 BACKGROUND Epidemiology Overall prevalence of juvenile rheumatoid arthritis is estimated to be from 30 - 150 per 100,000 children. In the United States and Canada there are an estimated 30,000 to 60,000 children and adolescents with juvenile rheumatoid arthritis. 5 BACKGROUND Pathogenesis and Etiology of JRA: Multi-factorial Genetic, Hormonal, Immunologic Pathogenesis Characterized by chronic inflammation of the synovium; Presence of articular cartilage damage; Accompanied by extra-articular systemic manifestations. Heterogeneity of JRA At least 3 primary types of onset of JRA: Pauciarticular (Oligoarticular) Polyarticular and Systemic 6 BACKGROUND Pathogenesis (Continued) Genetic Basis of immune distinction between self and non-self is the major histocompatibility complex (MHC) that in humans is called the human leukocyte antigen (HLA). HLA system comprises a family of polymorphic genes located on the short arm of chromosome 6. Polymorphisms of JRA suggest a non-mendelian inheritance. Hormonal Factors Differences in the sex ratio of JRA subtype onset Pre-adolescent or post-adolescent peaks 7 BACKGROUND Immune Mechanisms Disease process involves loss of tolerance towards auto-antigens  chronic synovitis; Production of auto-antibodies: Anti-nuclear antibodies (ANA): associated with increased risk of iridocyclitis (eye inflammation); Rheumatoid factors (RF): auto-antibodies directed against the Fc fragment of IgG (associated with ~10% of polyarticular JRA); Complement activation by circulating immune complexes may also contribute to the disease process. 8 BACKGROUND Immune Mechanisms (Continued) Cytokines: act on the immune system and other cells to initiate and sustain inflammation: Intercellular mediators: Interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-); Immunomodulatory cytokines produced by T-cells  Interferon gamma (IFN-γ), IL-4, IL-2. 9 CLASSIFICATION OF JUVENILE RHEUMATOID ARTHRITIS American College of Rheumatology (ACR) pediatric criterion for juvenile rheumatoid arthritis was established in 1977. 10 CLASSIFICATION OF JRA ACR Criteria Age at onset: < 16 years of age; Arthritis - swelling or effusion or the presence of 2 or more of the following signs: Limitation of range of motion, Tenderness or pain on motion and Increased heat in one or more joints; Duration of disease > 6 weeks; Onset type is defined by the type of disease in the first 6 months: Oligoarticular (Pauciarticular) < 5 inflamed joints; Polyarticular: > 5 inflamed joints; Systemic onset: arthritis with characteristic fever. Exclusion of other forms of childhood arthritis. Modified from JT Cassidy, JT Levinson, RM Laxer, CB Lindsley. Textbook of Pediatric Rheum. 2005 11 CLINICAL MANIFESTATIONS of JRA 12 Characteristic % Cases (F:M) # Joints Age at onset Systemic involvement Chronic Uveitis RF/ANA Prognosis Polyarticular 30 (3:1) > 5 Thru childhood, peak 1-3 yr Mild; unremitting articular involvement 5% 10%/40-50% Guarded to moderately good Pauciarticular 60 (5:1) < 4 Early childhood, peak 1-2 yr None; uveitis (++) 5-15% Rare/75-85% Excellent except for eyesight Systemic 10 (1:1) Variable Thru childhood, no peak Systemic self-limited; chronic destructive arthritis ~50% Rare Rare/10% Moderate to poor JRA by the Type-of-Onset JT Cassidy, RE Petty, RM Laxer, CB Lindsley. Textbook of Pediatric Rheumatology, 2005 13 Extra-Articular Manifestations of JRA Fever Rheumatoid rash Rheumatoid nodules Hepatosplenomegaly Lymphadenopathy Chronic uveitis Pericarditis Pleuritis Abdominal pain Polyarticular 30% 2 10 10 5 5 5 1 1 Pauciarticular 0% 0 0 0 0 20 0 0 0 Systemic 100% 95 5 85 70 1 35 20 10 JT Cassidy, RE Petty. Textbook of Pediatric Rheumatology, 2001 14 PROGNOSIS OF JRA Pauciarticular JRA Boys may be affected in older childhood or adolescence; this may represent an early manifestation of a spondyloarthropathy. Leg length discrepancy from asymmetric knee synovitis and bone growth may cause flexion contractures, gait abnormalities and long-term growth abnormalities. Eye involvement as anterior uveitis, may lead to scarring or blindness in ~ 15-20% of children. Active arthritis into adulthood in 40% to 50% of patients. Radiographic joint damage within 5 years. 15 PROGNOSIS OF JRA Polyarticular JRA and Systemic JRA Active arthritis into adulthood: 50% to 70% of polyarticular or systemic onset JRA; Long-term disabilities: 30% to 40% of children Unemployment: 25% to 50% of adult JRA patients; May need major surgery (joint replacement). Radiographic joint damage within 2 years; Mortality rate: 0.4% to 2% (greater risk with systemic JRA than with polyarticular JRA). 16 Traditional Approach to the Treatment of JRA Cytotoxic Drugs Disease Modifying Anti-Rheumatic Drugs (DMARDs) Intra-Articular/Oral Corticosteroids Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Before the 1990s … Pyramid Approach 17 Evolving Treatment of JRA Paradigm shift…. The trend in managing JRA is much more aggressive treatment earlier in the disease course with the goal of preventing joint damage and slowing progressive articular damage. Since the 1990s and into the 2000s… 18 Treatments with Indications for JRA Non-Selective NSAIDs Aspirin, tolmetin sodium, ibuprofen, naproxen Naproxen [Tablets and Suspension] Indicated for patients 2 years and older with juvenile arthritis. Daily dose: approximately 10 mg/kg/day as a BID dose (5 mg/kg given twice-a-day). Total daily dose is not to exceed 15 mg/kg/day. Adverse events: gastrointestinal, central nervous system (headache, dizziness, drowsiness, vertigo), rash (ecchymoses, purpura), pruritus, sweating, special senses (tinnitus, visual disturbances, hearing disturbances), cardiovascular (edema, palpitations) prolonged bleeding times. 19 Treatments with Indications for JRA Non-Selective NSAIDs/COX-2 Selective Inhibitors MOBIC (meloxicam) [Tablets and Suspension] Indicated for the relief of the signs and symptoms of pauciarticular and polyarticular course JRA in patients 2 yrs and older. 0.125 mg/kg once daily up to a maximum of 7.5 mg. Adverse events: abdominal pain/upper, vomiting, diarrhea, headache, infection (rhinitis), cough, pyrexia, rash. urticaria, slight increases in systolic blood pressure. VIOXX (rofecoxib) [Tablets and Suspension] Withdrawn from the global market September 2004. Indicated for the relief of the signs and symptoms of juvenile rheumatoid arthritis in patients 2 years and older. 20 Treatment of JRA Corticosteroids Used for uncontrolled or life-threatening systemic disease; Treatment of chronic uveitis as local ophthalmic drops; or Intra-articular agents (Pauci- and polyarticular JRA) Intermediate-acting corticosteroids: Prednisone; methyl-prednisolone (Intravenous pulse therapy for severely active JRA). Prednisone low-dose as 0.1 to 0.2 mg/kg; higher-dose 0.25 to 1.0 mg/kg/day (maximum single dose 40 mg) Adverse events: hypertension, iatrogenic Cushing’s syndrome, growth suppression, fractures, cataracts, increased susceptibility to infection. 21 Treatment of JRA DMARDs and Biologic DMARDs Methotrexate (MTX): used when NSAIDs fail to bring relief. Indicated for polyarticular JRA. MTX is the most widely used DMARD for JRA treatment. Starting dose 7.5 mg/m2 per week; maximum dose of 15 mg/m2 per week. Methotrexate compared to leflunomide (Lef): 240 JRA pts, 16-week DB + 6 mo Ext + optional 30 mo Ext in JRA; JRA Definition of Improvement > 30% (JRA DOI > 30): 89% MTX compared to 68% Lef. Adverse events: stomatitis, leukopenia, nausea/ abdominal pain, gastrointestinal bleeding, anorexia, malaise, fatigue, chills and fever, headache, alopecia, rash, decreased resistance to infection, elevated hepatic enzymes. 22 Treatment of JRA DMARDs and Biologic DMARDs (Continued) Sulfasalazine Indicated for polyarticular JRA who have responded inadequately to salicylates or other non-steroidal anti-inflammatory drugs. Children 6 yrs and older: 40 - 60 mg/kg/day divided into 3 to 6 doses. Maintenance dose: 30 mg/kg/day divided into 4 doses. Adverse events: anorexia, headache, vomiting, gastric distress, rash, urticaria, hemolytic anemia. 23 Treatment in JRA DMARDs and Biologic DMARDs (Continued) ENBREL (etanercept): a cytokine antagonist Indicated for moderate to severe polyarticular course JRA patients 4 to 17 years of age who had an inadequate response to one or more DMARDs. Dosage: 0.4 mg/kg/week (maximum 25 mg/ dose given twice weekly) as subcutaneous injection pre-filled syringe, 72-96 hrs. apart. Adverse events: headache, nausea, abdominal pain, and vomiting. Infection was reported in 43 of 69 (62%) of JRA patients during the 3-month (open-label phase). Serious AEs reported in the study: varicella, gastroenteritis, depression/ personality disorder, cutaneous ulcer, esophagitis/ gastritis, group A streptococcal septic shock, Type 1 diabetes, soft tissue and post-operative wound infection. 24 Treatment in JRA DMARDs indicated for RA without an indication for JRA Hydroxychloroquine, injectable gold, leflunomide and d-penicillamine. Other Immunomodulatory or Cytotoxic Drugs Indicated in RA without a JRA indication: Azathioprine Cyclosporine A Without a RA or a JRA indication: Chlorambucil Thalidomide 25 Treatment of JRA in 2006 Pauciarticular 25% to 33% will respond to NSAIDs; Patients not responsive to NSAIDS after 4 - 6 weeks with flexion contractures or leg length discrepancy  intra-articular corticosteroids. Patients with extended pauciarticular JRA or small joint involvement  treat as polyarticular JRA. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, pp 1671-1684. 26 Treatment of JRA in 2006 Polyarticular RF (-) or (+), NSAID (symptom control) alone is usually not as effective as a NSAID + DMARD. NSAID trial for several weeks  add oral MTX. If oral MTX is not effective  parenteral route MTX. If NSAID + MTX (oral or parenteral) is not effective  anti-TNF medication. No current evidence whether a combination of MTX + anti-TNF medication are more effective than only anti-TNF medication. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, pp 1671-1684. 27 Treatment of JRA in 2006 Systemic NSAIDs 2 to 3 weeks with caution  risk of Disseminated Intravascular Coagulation (DIC), (macrophage activation syndrome); Intravenous pulse methylprednisolone; Oral corticosteroids  Lowest effective dose; Steroid sparing  immunomodulatory approach is under evaluation for steroid sparing effects. Modified from Laxer R, Hashkes PJ. Medical Treatment of Juvenile Idiopathic Arthritis. JAMA, October 5, 2005. Vol 294, No. 13, p1671-1684. 28 CELEBREX (celecoxib) Non-Selective NSAID/COX-2 Selective Inhibitor Proposed Formulation: a capsule (50 mg, option to use as a sprinkle onto applesauce) Pivotal Study: 12-wk DB + 12-wk OL Ext (242 pts); celecoxib oral investigational suspension and naproxen oral suspension (active comparator) Proposed Dosing in Patients with JRA 50 mg capsule BID (100 mg/day): Patient weight 10 - 25 kg. 100 mg capsule BID (200 mg/day): Patient weight > 25 kg.
 

Frequently Asked Questions

> About SlidesFinder?

Slidesfinder is a website that allows users to upload and share their PowerPoint presentations online. It provides a platform for individuals and businesses to share their ideas and knowledge through presentations, and for others to view and download these presentations for educational or professional purposes.
Slidesfinder offers a wide range of presentation topics and categories, including business, education, science, technology, health, and more. Users can also search for presentations using keywords, tags, or by category. The website provides tools to create professional presentations with rich media, animations, and graphics.



One of the key features of Slidesfinder is its user-friendly interface, which allows users to easily upload, view, and share presentations. Users can also embed their presentations in their websites or blogs using the website's embed code feature.
Slidesfinder also offers premium services, such as the ability to create private presentations and to download presentations in high-quality formats. However, the basic features of Slidesfinder are free to use, making it accessible to anyone who wants to share their ideas and knowledge through presentations.

> How do I register with SlidesFinder?

Go to registration page (you can see signup link on top of website page) https://www.slidesfinder.com/signup . If you have facebook/gmail account them just click on SIGN IN WITH FACEBOOK OR SIGN IN WITH GOOGLE button, by this you will be a registered member of slidesfinder without filling any form, required detail automatically will be fatch from your account. If you do not a Facebook account, then click on "Signup". Fill all required fields and you will be a registered member of slidesfinder.

> Is slidesfinder account confirmation is mandatory?

Yes it is mandetory to active your account to login.

> Do I need to signup/login on SlidesFinder before uploading a PowerPoint presentation?

Yes, you need to login with your account before uploading presentation. Your username will be displayed on your uploaded presentation. Your registered email id is needed for sending your stats of uploaded presentation.

Slidesfinder is a sharing website for PowerPoint presentations search and share. Find your interest in the form of powerpoint presentations on slidesfinder and save your valuable time . On Slidesfinder you get presentations from our huge library of professional ppt presentations. We believe in making your search INFORMATIVE and FUN. Find your best ppt presentation from a pool of PowerPoint presentations stacked under important industry categories like business & management, heath & Wellness,eduction & training etc. We provide unique informative PowerPoint presentation for marketers, presenters and educationists. These professional PowerPoint presentations are uploaded by professionals from across numerous industry segments.These ppt presentations are available for FREE download.

Not just finding your interest, but facilitate you broadcast your interest. We have created this platform for easy sharing of PowerPoint presentations, ensuring that these presentations get maximum exposure. Create your slidesfinder account and upload PowerPoint presentations for free, share on social media platforms and BUILD YOUR CROWD WITH PRESENTATION !!

The Great Buddha says, "Share your knowledge.It’s a way to achieve immortality"! So, start sharing knowledge and we are here to make that immortal !!

© 2013-2024 SlidesFinder. All rights reserved.

Re-productivity of content are not allowed. Without prior written permission from author, commercial use of any content is illegal.